GlassScriptPhysician profile
Ashley Mccloud
NPI 1174835201
$1,603.41
in general payments reported to CMS, 2019-2025
32 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.27 · 2020: $204 · 2021: $353 · 2022: $236 · 2023: $181 · 2024: $225 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $189.17 | 2021-2023 | Ova1 |
| Astellas Pharma US INC | $166.52 | 2023-2025 | Veozah |
| Pfizer INC. | $141.47 | 2019-2023 | |
| Abbvie INC. | $138.56 | 2020-2022 | |
| Sage Therapeutics, LLC | $98.65 | 2023-2025 | Zurzuvae |
| Minerva Surgical, INC | $91.37 | 2020-2025 | |
| Daiichi Sankyo INC. | $84.35 | 2019-2021 | |
| Scynexis, INC. | $70.30 | 2021-2022 | |
| Exeltis, USA INC. | $63.23 | 2020-2024 | Slynd |
| Hologic Sales and Service, LLC | $47.57 | 2024-2025 | Myosure Tissue Removal Device, Aptima, Fluent Fluid Management System |
| Shield Therapeutics INC | $46.82 | 2024-2025 | |
| Myovant Sciences INC. | $42.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.35 | 2022-2023 | |
| Therapeuticsmd, INC. | $41.73 | 2020-2022 | |
| Channel Medsystems, INC. | $41.35 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $32.86 | 2025 | |
| Mylan Pharmaceuticals INC. | $24.11 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $22.05 | 2025 | Gemtesa |
| Agile Therapeutics, INC. | $21.73 | 2024 | Twirla |
| Exact Sciences Corporation | $19.54 | 2025 | The Cologuard Plus Collection Kit |
| Supernus Pharmaceuticals, INC. | $19.14 | 2025 | Qelbree |
| Organon LLC | $18.77 | 2025 | Nexplanon, Jada System |
| Conmed Corporation | $18.30 | 2019 | |
| Medline Industries LP | $15.65 | 2024 | |
| Axonics, INC. | $15.32 | 2024 | Axonics |
| Vertex Pharmaceuticals Incorporated | $14.88 | 2025 | |
| Evofem Biosciences, INC. | $14.43 | 2021 | |
| Avion Pharmaceuticals | $12.99 | 2020 | |
| Lupin INC. | $12.70 | 2020 | |
| Meditrina | $11.80 | 2024 | |
| Merck Sharp & Dohme LLC | $11.61 | 2021 | |
| Allergan, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mccloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.